Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biohaven (BHVN) Cash & Equivalents (2021 - 2026)

Biohaven has reported Cash & Equivalents over the past 6 years, most recently at $273.1 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $273.1 million for Q1 2026, up 177.47% from a year ago — trailing twelve months through Mar 2026 was $273.1 million (up 177.47% YoY), and the annual figure for FY2025 was $230.0 million, up 131.97%.
  • Cash & Equivalents reached $273.1 million in Q1 2026 per BHVN's latest filing, up from $230.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $273.1 million in Q1 2026 and bottomed at $23.2 million in Q2 2022.
  • Median Cash & Equivalents over the past 5 years was $147.6 million (2023), compared with a mean of $147.6 million.
  • The largest annual shift saw Cash & Equivalents tumbled 85.99% in 2022 before it skyrocketed 536.01% in 2023.
  • Over 5 years, Cash & Equivalents stood at $204.9 million in 2022, then grew by 21.24% to $248.4 million in 2023, then tumbled by 60.09% to $99.1 million in 2024, then soared by 131.97% to $230.0 million in 2025, then rose by 18.75% to $273.1 million in 2026.
  • Business Quant data shows Cash & Equivalents for BHVN at $273.1 million in Q1 2026, $230.0 million in Q4 2025, and $184.8 million in Q3 2025.